Literature DB >> 24900547

Fluorescent Human EP3 Receptor Antagonists.

Miriam Tomasch1, J Stephan Schwed1, Karina Kuczka2, Sascha Meyer Dos Santos2, Sebastian Harder2, Rolf M Nüsing2, Alexander Paulke3, Holger Stark1.   

Abstract

Exchange of the lipophilc part of ortho-substituted cinnamic acid lead structures with different small molecule fluorophoric moieties via a dimethylene spacer resulted in hEP3R ligands with affinities in the nanomolar concentration range. Synthesized compounds emit fluorescence in the blue, green, and red range of light and have been tested concerning their potential as a pharmacological tool. hEP3Rs were visualized by confocal laser scanning microscopy on HT-29 cells, on murine kidney tissues, and on human brain tissues and functionally were characterized as antagonists on human platelets. Inhibition of PGE2 and collagen-induced platelet aggregation was measured after preincubation with novel hEP3R ligands. The pyryllium-labeled ligand 8 has been shown as one of the most promising structures, displaying a useful fluorescence and highly affine hEP3R antagonists.

Entities:  

Keywords:  EP3 receptor; GPCR; cinnamic acid derivatives; confocal laser scanning microscopy; fluorescence; human brain; imaging; murine kidney; platelet aggregation; prostanoid

Year:  2012        PMID: 24900547      PMCID: PMC4025810          DOI: 10.1021/ml300191g

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor.

Authors:  H Juteau; Y Gareau; M Labelle; C F Sturino; N Sawyer; N Tremblay; S Lamontagne; M C Carrière; D Denis; K M Metters
Journal:  Bioorg Med Chem       Date:  2001-08       Impact factor: 3.641

2.  Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists.

Authors:  Michel Belley; Michel Gallant; Bruno Roy; Karine Houde; Nicolas Lachance; Marc Labelle; Laird A Trimble; Nathalie Chauret; Chun Li; Nicole Sawyer; Nathalie Tremblay; Sonia Lamontagne; Marie-Claude Carrière; Danielle Denis; Gillian M Greig; Deborah Slipetz; Kathleen M Metters; Robert Gordon; Chi Chung Chan; Robert J Zamboni
Journal:  Bioorg Med Chem Lett       Date:  2005-02-01       Impact factor: 2.823

3.  Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.

Authors:  Max Keller; Daniela Erdmann; Nathalie Pop; Nikola Pluym; Shangjun Teng; Günther Bernhardt; Armin Buschauer
Journal:  Bioorg Med Chem       Date:  2011-04-12       Impact factor: 3.641

4.  Fluorescent non-imidazole histamine H3 receptor ligands with nanomolar affinities.

Authors:  Michael Amon; Xavier Ligneau; Jean-Charles Schwartz; Holger Stark
Journal:  Bioorg Med Chem Lett       Date:  2006-01-24       Impact factor: 2.823

5.  Identification and localization of prostaglandin E2 receptors in upper and lower segment human myometrium during pregnancy.

Authors:  Shirley Astle; Steven Thornton; Donna M Slater
Journal:  Mol Hum Reprod       Date:  2005-02-18       Impact factor: 4.025

6.  Distinct cellular localization of mRNAs for three subtypes of prostaglandin E receptor in kidney.

Authors:  Y Sugimoto; T Namba; R Shigemoto; M Negishi; A Ichikawa; S Narumiya
Journal:  Am J Physiol       Date:  1994-05

7.  Enhanced bladder capacity and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice.

Authors:  Gerald P McCafferty; Blake A Misajet; Nicholas J Laping; Richard M Edwards; Kevin S Thorneloe
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-28

8.  Highly potent fluorescence-tagged nonimidazole histamine H3 receptor ligands.

Authors:  Michael Amon; Xavier Ligneau; Jean-Claude Camelin; Isabelle Berrebi-Bertrand; Jean-Charles Schwartz; Holger Stark
Journal:  ChemMedChem       Date:  2007-05       Impact factor: 3.466

9.  Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.

Authors:  Jasbir Singh; Wayne Zeller; Nian Zhou; Georgeta Hategen; Rama Mishra; Alex Polozov; Peng Yu; Emmanuel Onua; Jun Zhang; David Zembower; Alex Kiselyov; José L Ramírez; Gudmundur Sigthorsson; Jon Mar Bjornsson; Margret Thorsteinsdottir; Thorkell Andrésson; Maria Bjarnadottir; Olafur Magnusson; Jean-Etienne Fabre; Kari Stefansson; Mark E Gurney
Journal:  ACS Chem Biol       Date:  2009-02-20       Impact factor: 5.100

10.  Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2.

Authors:  Ivonne Löffler; Michael Grün; Frank D Böhmer; Ignacio Rubio
Journal:  BMC Cancer       Date:  2008-12-19       Impact factor: 4.430

View more
  5 in total

Review 1.  The evolving small-molecule fluorescent-conjugate toolbox for Class A GPCRs.

Authors:  Andrea J Vernall; Stephen J Hill; Barrie Kellam
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 2.  Perspectives on medicinal properties of natural phenolic monoterpenoids and their hybrids.

Authors:  Jamatsing D Rajput; Suresh D Bagul; Umesh D Pete; Chetan M Zade; Subhash B Padhye; Ratnamala S Bendre
Journal:  Mol Divers       Date:  2017-10-07       Impact factor: 2.943

3.  A Non-imaging High Throughput Approach to Chemical Library Screening at the Unmodified Adenosine-A3 Receptor in Living Cells.

Authors:  Maria Augusta Arruda; Leigh A Stoddart; Karolina Gherbi; Stephen J Briddon; Barrie Kellam; Stephen J Hill
Journal:  Front Pharmacol       Date:  2017-12-13       Impact factor: 5.810

Review 4.  Effects of Arachidonic Acid and Its Metabolites on Functional Beta-Cell Mass.

Authors:  Karin J Bosma; Cecilia E Kaiser; Michelle E Kimple; Maureen Gannon
Journal:  Metabolites       Date:  2022-04-12

5.  Synthesis of Bio-Inspired 1,3-Diarylpropene Derivatives via Heck Cross-Coupling and Cytotoxic Evaluation on Breast Cancer Cells.

Authors:  Aik Sian Tan; Jaymeer Singh; Nurul Syafiqah Rezali; Musthahimah Muhamad; Nik Nur Syazni Nik Mohamed Kamal; Yvan Six; Mohamad Nurul Azmi
Journal:  Molecules       Date:  2022-08-23       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.